Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases

Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases

BackgroundOur previous study suggested CD36 may be a positive regulator of hepatitis B virus (HBV) replication in vitro. Therefore, the present study aimed to investigate whether circulating soluble CD36 (sCD36) could serve as a diagnostic and prognostic biomarker for HBV-related liver diseases base...

Full description

Bibliographic Details
Main Authors:	Chunxian Cai, Anhua Xiao, Xiaoqing Luo, Enze Zheng, Yiyu Li, Yu Lei, Shan Zhong, Yaxi Chen, Ping Yang, Zhurong Tang, Zhi Zhou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-11-01
Series:	Frontiers in Microbiology
Subjects:	sCD36 biomarker HBV-related liver diseases cirrhosis liver failure
Online Access:	https://www.frontiersin.org/articles/10.3389/fmicb.2022.1039614/full

Similar Items

The polymorphism analysis for CD36 among platelet donors
by: Qilu Lyu, et al.
Published: (2024-04-01)

Impact of the interaction between the polymorphisms and hypermethylation of the CD36 gene on a new biomarker of type 2 diabetes mellitus: circulating soluble CD36 (sCD36) in Senegalese females
by: Maïmouna Touré, et al.
Published: (2022-08-01)

Association of Circulating Markers of Microbial Translocation and Hepatic Inflammation with Liver Injury in Patients with Type 2 Diabetes
by: Leila Gobejishvili, et al.
Published: (2024-05-01)

PLASMA LEVEL OF SOLUBLE CD30 IN PEDIATRIC LIVING-DONOR LIVER TRANSPLANT PATIENT
by: O. P. Shevchenko, et al.
Published: (2011-12-01)

Serum levels of sCD36 and cardiometabolic variables in two Peruvian towns: Carhuamayo (4100 masl) and Mala (30 masl)
by: Elizabeth Carranza Alva, et al.
Published: (2017-03-01)

RELATIVE FREQUENCY OF HEPATITIS B VIRUS AND HEPATITIS C VIRUS INFECTIONS IN PATIENTS OF LIVER CIRRHOSIS IN CHILDREN
by: Syed Nizam Hussain Shah, et al.
Published: (2020-02-01)

Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis
by: Rasmus Hvidbjerg Gantzel, et al.
Published: (2021-01-01)

Macrophage Activation Markers, CD163 and CD206, in Acute-on-Chronic Liver Failure
by: Marlene Christina Nielsen, et al.
Published: (2020-05-01)

Adaptive Subsets Limit the Anti-Tumoral NK-Cell Activity in Hepatocellular Carcinoma
by: Charlotte Rennert, et al.
Published: (2021-06-01)

Hepatic and extrahepatic metabolic modulation in hbv-related decompensated cirrhosis and acute-on-chronic liver failure
by: Zhi-Wei Li, et al.
Published: (2024-12-01)

The comparative description of clinical course, injury an regeneration of liver while chronic HBV- and HCV- infections course
by: V. E. Karev, et al.
Published: (2014-09-01)

Elevated circulating soluble interleukin-2 receptor in patients with chronic liver diseases is associated with non-classical monocytes
by: Seidler Sebastian, et al.
Published: (2012-04-01)

Combined Blockade of Lipid Uptake and Synthesis by CD36 Inhibitor and SCD1 siRNA Is Beneficial for the Treatment of Refractory Prostate Cancer
by: Jiyuan Chen, et al.
Published: (2025-02-01)

Treatment of patients with HBV cirrhosis: Successes, unsolved problems
by: I G Bakulin, et al.
Published: (2013-12-01)

The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation
by: Sara Battistella, et al.
Published: (2023-04-01)

Nucleoside analogues in treatment of liver cirrhosis as an outcome of chronic hepatitis B
by: I. G. Bakulin
Published: (2009-02-01)

Liver transplantation for HBV-related liver disease: Impact of prophylaxis for HBV on HCC recurrence
by: Patrizia Burra, et al.
Published: (2025-03-01)

Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase
by: Jian Wang, et al.
Published: (2024-06-01)

The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection
by: D. V. Garbuzenko
Published: (2021-11-01)

Seroprevalence and genotypic characterization of HBV among low risk voluntary blood donors in Nairobi, Kenya
by: Patrick Okoti Aluora, et al.
Published: (2020-11-01)

High hepatic macrophage activation and low liver function in stable Wilson patients - a Danish cross-sectional study
by: Jessica Björklund, et al.
Published: (2018-09-01)

Soluble CD206 and CD163 as novel prognostic biomarkers in adult acute myeloid leukemia
by: Haifa A. Al-Matari, et al.
Published: (2024-11-01)

IL‐15‐induced CD38+HLA‐DR+CD8+ T cells correlate with liver injury via NKG2D in chronic hepatitis B cirrhosis
by: Jing Fan, et al.
Published: (2024-01-01)

Interpretation US Elastography in Chronic Hepatitis B with or without Anti-HBV Therapy
by: Cheng-Han Lee, et al.
Published: (2017-11-01)

HBsAg level defines different clinical phenotypes of HBeAg(−) chronic HBV infection related to HBV polymerase-specific CD8+ cell response quality
by: Julia Peña-Asensio, et al.
Published: (2024-03-01)

Editorial: The current challenges underlying hepatitis D virus infection
by: Romina Salpini, et al.
Published: (2024-01-01)

Hepatitis B vaccination coverage among healthcare workers at national hospital in Tanzania: how much, who and why?
by: Dotto Aaron, et al.
Published: (2017-12-01)

Illuminating HBV with multi-scale modeling
by: Shawn A. Means, et al.
Published: (2023-02-01)

Soluble CD27 and MIF as possible serum biomarkers of vitiligo activity in Egyptian patients in Sharkia Governorate
by: Mohamed Ibrahim El-Ghareeb, et al.
Published: (2019-12-01)

Management of HBV Infection in Liver Transplantation Patients
Published: (2005-01-01)

Association of hepatitis B virus treatment with all-cause and liver-related mortality among individuals with HBV and cirrhosis: a population-based cohort studyResearch in context
by: Jean Damascene Makuza, et al.
Published: (2024-08-01)

Serum Iron Levels Decreased in Patients with HBV-Related Hepatocellular Carcinoma, as a Risk Factor for the Prognosis of HBV-Related HCC
by: Yanyan Wei, et al.
Published: (2018-02-01)

Evaluation of the HBV liver reservoir with fine needle aspirates
by: Barbara Testoni, et al.
Published: (2023-10-01)

Engineering HBV-specific T cells for the treatment of HBV-related HCC and HBV infection: Past, Present, and Future. Editorial on “Genetically-modified, redirected T cells target hepatitis B surface antigen-positive hepatocytes and hepatocellular carcinoma lesions in a clinical setting”
by: Antonio Bertoletti, et al.
Published: (2024-10-01)

Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues?
by: Isabel Campos-Varela, et al.
Published: (2011-04-01)

Single-cell RNA transcriptomics reveals differences in the immune status of alcoholic and hepatitis B virus-related liver cirrhosis
by: Pengpeng Zhang, et al.
Published: (2023-02-01)

Validation of Hepatocellular Carcinoma Risk Prediction Models in Patients with Hepatitis B-Related Cirrhosis
by: Cheng R, et al.
Published: (2022-09-01)

Hepatitis Delta Virus and Hepatocellular Carcinoma
by: Daniele Lombardo, et al.
Published: (2024-04-01)

Study on pathological and clinical characteristics of chronic HBV infected patients with HBsAg positive, HBV DNA negative, HBeAg negative
by: Zhan Zeng, et al.
Published: (2023-01-01)

A retrospective case-series of influence of chronic hepatitis B on synchronous liver metastasis of colorectal cancer
by: Lin Zhu, et al.
Published: (2023-02-01)